Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network
Here presented data indicates that treatment with dupilumab for AD has reduced risk for adverse effects of conventional systemic drugs and thus might be safer. Obtained data should be verified in prospective studies.
Authors
- Ralf Joachim Ludwig (ORCID: https://orcid.org/0000-0002-1394-1737)
- Sascha Ständer (ORCID: https://orcid.org/0000-0003-0183-0375)
- Henner Zirpel (ORCID: https://orcid.org/0000-0003-0053-4312)
- Khalaf Kridin (ORCID: https://orcid.org/0000-0001-9971-9151)
- Henning Olbrich (ORCID: https://orcid.org/0000-0003-0863-7148)
- Diamant Thaçi (ORCID: https://orcid.org/0000-0001-8513-550X)
Institutions
- Bar-Ilan University (IL)
- Western Galilee Hospital (IL)
- University of Lübeck (DE)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2024-11-03
- DOI
- https://doi.org/10.1080/09546634.2024.2421429
- Citations
- 4
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.14
Funders
- Deutsche Forschungsgemeinschaft